References
- Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014;123(20):3073–9.
- Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017–4023.
- Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 2014;28:391–397.
- Silvennoinen R, Lundan T, Kairisto V, et al. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma. Blood Cancer J 2014;4:e250–e257.
- Puig N, Sarasquete M, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 2014;28:391–398.
- Prideaux SM, O’Brien CE, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol 2014;2014:335–348.
- Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol 2013;97:313–322.
- Walker B, Leone P, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010;116:56–65.
- Pohl G, Shih M. Principle and applications of digital PCR. Expert Rev Mol Diagn 2004;4:41–47.
- Zhu Q, Qiu L, Yu B, et al. Digital PCR on an integrated self-priming compartmentalization chip. Lab Chip 2013;14:1176–1185.